We evaluated HSN608 and HSN748 on primary de novo AMLs, drug-resistant AMLs, and relapsed/refractory AMLs with FLT3ITD mutations, as well as in vivo genetic models including mice bearing Tet2 and FLT3ITD and cells from AML patient-derived PDXs. The gene discussed is TET2; the disease is acute myeloid leukemia.